Ewenstein BM - Search Results

1

IgE-mediated allergy and desensitization to factor IX in hemophilia B.

Dioun AF, Ewenstein BM, Geha RS, Schneider LC. Dioun AF, et al. Among authors: ewenstein bm. J Allergy Clin Immunol. 1998 Jul;102(1):113-7. doi: 10.1016/s0091-6749(98)70061-2. J Allergy Clin Immunol. 1998. PMID: 9679854

2

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.

Dharnidharka VR, Takemoto C, Ewenstein BM, Rosen S, Harris HW. Dharnidharka VR, et al. Among authors: ewenstein bm. Pediatr Nephrol. 1998 Oct;12(8):654-7. doi: 10.1007/s004670050522. Pediatr Nephrol. 1998. PMID: 9811389

3

Factor IX inhibitors and anaphylaxis in hemophilia B.

Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Katz J, Bergmann F, Ljung R, Petrini P, Lusher JM. Warrier I, et al. Among authors: ewenstein bm. J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):23-7. doi: 10.1097/00043426-199701000-00003. J Pediatr Hematol Oncol. 1997. PMID: 9065715

4

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA; Mononine Comparison Study Group. Ewenstein BM, et al. Transfusion. 2002 Feb;42(2):190-7. doi: 10.1046/j.1537-2995.2002.00039.x. Transfusion. 2002. PMID: 11896334

5

The economic impact of factor VIII inhibitors in patients with haemophilia.

Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. Bohn RL, et al. Among authors: ewenstein bm. Haemophilia. 2004 Jan;10(1):63-8. doi: 10.1046/j.1365-2516.2003.00849.x. Haemophilia. 2004. PMID: 14962222

6

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.

Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Colowick AB, et al. Among authors: ewenstein bm. Blood. 2000 Sep 1;96(5):1698-702. Blood. 2000. PMID: 10961866 Free article.

7

A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.

Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. Putnam KG, et al. Among authors: ewenstein bm. Haemophilia. 2005 May;11(3):261-9. doi: 10.1111/j.1365-2516.2005.01098.x. Haemophilia. 2005. PMID: 15876272

8

Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation.

Wise RJ, Ewenstein BM, Gorlin J, Narins SC, Jesson M, Handin RI. Wise RJ, et al. Among authors: ewenstein bm. Hum Genet. 1993 May;91(4):367-72. doi: 10.1007/BF00217358. Hum Genet. 1993. PMID: 8500791 Review.

9

Porcine factor VIII: pharmacoeconomics of inhibitor therapy.

Ewenstein BM, Avorn J, Putnam KG, Bohn RL. Ewenstein BM, et al. Haemophilia. 2002 Jan;8 Suppl 1:13-6; discussion 28-32. doi: 10.1046/j.1365-2516.2002.00135.x. Haemophilia. 2002. PMID: 11882077

10

The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding.

Ewenstein BM. Ewenstein BM. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 2):770-7. doi: 10.1016/s0002-9378(96)80083-4. Am J Obstet Gynecol. 1996. PMID: 8828560 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters